{"id":25023,"date":"2024-02-06T12:12:23","date_gmt":"2024-02-06T11:12:23","guid":{"rendered":"https:\/\/idibell.cat\/?p=25023"},"modified":"2024-02-06T12:31:37","modified_gmt":"2024-02-06T11:31:37","slug":"descobreixen-alteracions-del-sistema-immunologic-sanguini-que-augmenten-el-risc-de-cancer","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2024\/02\/descobreixen-alteracions-del-sistema-immunologic-sanguini-que-augmenten-el-risc-de-cancer\/","title":{"rendered":"Descobreixen alteracions del sistema immunol\u00f2gic sanguini que augmenten el risc de c\u00e0ncer"},"content":{"rendered":"

L\u2019estudi liderat per investigadors\/es de l\u2019Institut Catal\u00e0 d\u2019Oncologia (ICO), l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), l’Institut de Recerca Germans Trias i Pujol (IGTP), i el Translational Genomics Research Institute d\u2019Estats Units, s\u2019ha publicat a la revista \u2018Genome Medicine<\/strong><\/a>\u2019 i representa un pas significatiu cap a una millor comprensi\u00f3 de com les alteracions en el sistema immunol\u00f2gic faciliten l’aparici\u00f3 del c\u00e0ncer.<\/p>\n

El sistema immunitari \u00e9s el responsable de mantenir la integritat i funci\u00f3 de l’organisme protegint-nos cont\u00ednuament d\u2019atacs ex\u00f2gens, com poden ser els virus, i end\u00f2gens, en aquest cas, el c\u00e0ncer. Aix\u00f2, li atorga un paper central en la inhibici\u00f3 de la carcinog\u00e8nesi i la seva alteraci\u00f3 pot augmentar el risc de c\u00e0ncer en permetre la proliferaci\u00f3 de c\u00e8l\u00b7lules malignes. Tot i aix\u00f2, la base gen\u00e8tica que influeix en aquesta regulaci\u00f3 era generalment desconeguda fins ara. Ara, aquesta investigaci\u00f3 obre noves vies per al desenvolupament de m\u00e8todes de prevenci\u00f3 espec\u00edfics i dirigits a trav\u00e9s de ter\u00e0pies o intervencions que modulin la resposta immunol\u00f2gica.<\/p>\n

Els resultats del projecte senyalen a m\u00e9s de 1.000 gens que influeixen simult\u00e0niament en el sistema immunitari i el risc de c\u00e0ncer. Aquests gens que afecten a m\u00e9s d\u2019una caracter\u00edstica de l\u2019organisme, anomenats pleiotr\u00f2pics, es troben sovint associats al control del desenvolupament del sistema hematol\u00f2gic i la regulaci\u00f3 dels tel\u00f2mers.<\/p>\n

Per una banda, l\u2019alteraci\u00f3 de l\u2019hematopoesi associada a c\u00e0ncer es vincula principalment amb anomalies de c\u00e8l\u00b7lules del tipus mieloide, com els neutr\u00f2fils o els eosin\u00f2fils. En aquest sentit, l\u2019estudi ha determinat un paper protector espec\u00edfic dels eosin\u00f2fils contra el desenvolupament de c\u00e0ncers comuns a la poblaci\u00f3 general. Per altra banda, els tel\u00f2mers s\u00f3n estructures situades als extrems dels cromosomes que protegeixen el material gen\u00e8tic i que es desgasten amb el pas del temps. Pel que, alteracions dels tel\u00f2mers, s\u2019associen a diferents patologies o condicions, incloent-hi el c\u00e0ncer i l\u2019envelliment.<\/p>\n

A m\u00e9s, l\u2019estudi ha identificat possibles biomarcadors sanguinis de risc de c\u00e0ncer i inici de tumors. Aquests marcadors predictius es basen en petites seq\u00fc\u00e8ncies de RNA no-codificant que poden alterar la funci\u00f3 del sistema immunitari.<\/p>\n

Pel responsable de l\u2019estudi i cap del Programa ProCURE de l\u2019ICO, Miquel \u00c0ngel Pujana<\/a>, tamb\u00e9 investigador de l\u2019IDIBELL: \u201cAquest estudi obre noves vies per a la millora de la prevenci\u00f3 del c\u00e0ncer de forma personalitzada, i les troballes podrien conduir a estrat\u00e8gies preventives m\u00e9s espec\u00edfiques, adaptades a les caracter\u00edstiques gen\u00e8tiques individuals<\/strong>\u201d.<\/p>\n

 <\/p>\n

\"Equip
Equip GCAT!Genomes for Life-IGTP<\/figcaption><\/figure>\n

El Dr. Rafael de Cid, co-responsable de l\u2019estudi i cap del projecte GCAT!Genomes for Life- IGTP, destaca la complexitat i la interconnexi\u00f3 de l’arquitectura del genoma hum\u00e0: \u201cLa recerca gen\u00e8tica centrada en trets biol\u00f2gics mesurables, senzills, pot ser una via per entendre les bases gen\u00e8tiques de trets m\u00e9s complexos, com el c\u00e0ncer<\/strong>\u201d.<\/p>\n

En resum, els autors subratllen la import\u00e0ncia del progr\u00e9s en la recerca gen\u00e8tica per millorar la prevenci\u00f3 i el tractament del c\u00e0ncer, cap a una personalitzaci\u00f3 d’aquestes intervencions.<\/p>\n

Els primers co-autors del treball s\u00f3n Miguel Angel Pardo (ICO-IDIBELL, programa PERIS-Salut), Xavier Farr\u00e9 (GCAT), Anna Esteve (ICO-IGTP), Joanna Palade (TGen) i Roderic Esp\u00edn (ICO-IDIBELL, programa PERIS-Salut).<\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

L\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l\u2019Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l\u2019Institut Catal\u00e0 de la Salut, l\u2019Institut Catal\u00e0 d\u2019Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/span><\/i>\u00a0<\/span><\/p>\n

L\u2019IDIBELL \u00e9s membre del Campus d\u2019Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L\u2019any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/span><\/i><\/p>\n","protected":false},"excerpt":{"rendered":"

Un equip internacional d\u2019investigadors identifica la base gen\u00e8tica i els processos biol\u00f2gics que influeixen en el risc de c\u00e0ncer relacionat amb alteracions en el nombre de c\u00e8l\u00b7lules immunol\u00f2giques presents a la sang.<\/p>\n","protected":false},"author":8,"featured_media":25024,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[332,390,447,452],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-23 21:45:12","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/25023"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=25023"}],"version-history":[{"count":5,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/25023\/revisions"}],"predecessor-version":[{"id":25031,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/25023\/revisions\/25031"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/25024"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=25023"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=25023"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=25023"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}